Stryker Co. (NYSE:SYK) Shares Sold by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC reduced its stake in Stryker Co. (NYSE:SYK) by 26.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,198 shares of the medical technology company’s stock after selling 5,928 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Stryker were worth $5,852,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Headlands Technologies LLC lifted its position in Stryker by 203.1% during the 1st quarter. Headlands Technologies LLC now owns 585 shares of the medical technology company’s stock worth $209,000 after acquiring an additional 392 shares during the period. Koshinski Asset Management Inc. acquired a new stake in shares of Stryker during the first quarter worth about $795,000. Kingsview Wealth Management LLC increased its holdings in Stryker by 0.3% in the 1st quarter. Kingsview Wealth Management LLC now owns 14,166 shares of the medical technology company’s stock worth $5,069,000 after buying an additional 47 shares during the period. Lord Abbett & CO. LLC lifted its stake in Stryker by 5.0% during the 1st quarter. Lord Abbett & CO. LLC now owns 821 shares of the medical technology company’s stock valued at $294,000 after acquiring an additional 39 shares during the period. Finally, Blair William & Co. IL boosted its holdings in shares of Stryker by 5.0% in the 1st quarter. Blair William & Co. IL now owns 926,578 shares of the medical technology company’s stock valued at $331,595,000 after acquiring an additional 44,093 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In related news, VP M Kathryn Fink sold 7,347 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the transaction, the vice president now owns 10,042 shares in the company, valued at $3,685,213.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the completion of the transaction, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 67,381 shares of company stock worth $24,825,275. 5.50% of the stock is owned by company insiders.

Stryker Price Performance

Shares of NYSE:SYK opened at $387.11 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. Stryker Co. has a 12 month low of $276.60 and a 12 month high of $388.12. The firm has a market capitalization of $147.57 billion, a P/E ratio of 41.49, a P/E/G ratio of 2.86 and a beta of 0.91. The company’s fifty day moving average price is $361.83 and its 200 day moving average price is $346.06.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. The business had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The company’s revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.46 earnings per share. As a group, sell-side analysts predict that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on SYK shares. UBS Group raised their price objective on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Evercore ISI increased their price target on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Citigroup upped their target price on Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. JPMorgan Chase & Co. boosted their price target on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. Finally, Truist Financial increased their price objective on shares of Stryker from $370.00 to $380.00 and gave the company a “hold” rating in a report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $393.65.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.